Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $301,000.

  • IDEAYA Biosciences' Cash from Financing Activities fell 99.89% to $301,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year decrease of 96.27%. This contributed to the annual value of $677.6 million for FY2024, which is 86.80% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Cash from Financing Activities stood at $301,000, which was down 75.02% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, IDEAYA Biosciences' Cash from Financing Activities peaked at $349.1 million during Q1 2024, and registered a low of $301,000 during Q3 2025.
  • Over the past 3 years, IDEAYA Biosciences' median Cash from Financing Activities value was $27.8 million (recorded in 2023), while the average stood at $97.1 million.
  • As far as peak fluctuations go, IDEAYA Biosciences' Cash from Financing Activities surged by 123,441.18% in 2021, and later plummeted by 99.89% in 2025.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Cash from Financing Activities stood at $688,000 in 2021, then crashed by 52.91% to $324,000 in 2022, then soared by 43,385.80% to $140.9 million in 2023, then crashed by 98.05% to $2.8 million in 2024, then crashed by 99.89% to $301,000 in 2025.
  • Its last three reported values are $301,000 in Q3 2025, $1.2 million for Q2 2025, and $26.1 million during Q1 2025.